Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Iberis amara
European bitter herb used historically for cardiac and respiratory conditions; now validated for dyspepsia treatment.
Iberis amara (bitter candytuft) is a European herb traditionally used for cardiac and respiratory conditions, but modern research focuses on its digestive benefits, particularly in dyspepsia and irritable bowel syndrome. Its primary active compounds include cucurbitacin E, kaempferol, quercetin, and glucoiberin, which contribute to its anti-inflammatory, antispasmodic, and digestive stimulant properties. Clinical evidence is limited (Grade C), but it is a key component of the proprietary Iberogast formulation.
Cucurbitacin E acts as a bitter agonist on TAS2R receptors in the oral cavity and gut, stimulating gastric acid secretion and motility via vagal reflexes. Flavonoids like kaempferol and quercetin inhibit COX-2 and NF-κB pathways, reducing gastrointestinal inflammation. The herb also exhibits antispasmodic effects through calcium channel blockade in smooth muscle, while glucoiberin contributes to antioxidant activity via the Nrf2 pathway.
European bitter herb used historically for cardiac and respiratory conditions; now validated for dyspepsia treatment.
Iberis amara (bitter candytuft) is a European herb traditionally used for cardiac and respiratory conditions, but modern research focuses on its digestive benefits, particularly in dyspepsia and irritable bowel syndrome. Its primary active compounds include cucurbitacin E, kaempferol, quercetin, and glucoiberin, which contribute to its anti-inflammatory, antispasmodic, and digestive stimulant properties. Clinical evidence is limited (Grade C), but it is a key component of the proprietary Iberogast formulation.
Cucurbitacin E acts as a bitter agonist on TAS2R receptors in the oral cavity and gut, stimulating gastric acid secretion and motility via vagal reflexes. Flavonoids like kaempferol and quercetin inhibit COX-2 and NF-κB pathways, reducing gastrointestinal inflammation. The herb also exhibits antispasmodic effects through calcium channel blockade in smooth muscle, while glucoiberin contributes to antioxidant activity via the Nrf2 pathway.